In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. These experimental medicines are still a few years from possible approval. Veru ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study ... 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% ...

Veru was first with results in January from a 168-person trial, showing its enobosarm helped older patients lose 71% less muscle when taken with Wegovy. Data on Lilly's muscle mass-preserving drug ...

Veru had a pre-IND meeting with the FDA Division ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes ...

Veru had a pre-IND meeting with the FDA Division of Cardiology ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular ...